EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic

Núria Mercadé-Besora iD, Yuchen Guo, Mike Du, Xintong Li, Juan Manuel Ramírez-Anguita, Alberto Moreno, António Valente, Felipe Villalobos, Iek Leng Cheng, Lucía A Carrasco-Ribelles, Maaike M H van Swieten, Manon Merkelbach und 17 weitere

Arthritis Care & Research · 2024

DOI: 10.1002/acr.25331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Núria Mercadé-Besora und 28 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaco- and Device Epidemiology Group, Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculos…. Hauptthemen laut MEDLINE: Hydroxychloroquine, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovative Medicines Initiative (IMI), NIHR Senior Research Fellowship, NIHR, International Magnesium Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We studied whether the use of hydroxychloroquine (HCQ) for COVID‐19 resulted in supply shortages for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Methods

We used US claims data (IQVIA PHARMETRICS® Plus for Academics [PHARMETRICS]) and hospital electronic records from Spain (Institut Municipal d'Assistència Sanitària Information System [IMASIS]) to estimate monthly rates of HCQ use between January 2019 and March 2022, in the general population and in patients with RA and SLE. Methotrexate (MTX) use was estimated as a control.

Results

More than 13.5 million individuals (13,311,811 PHARMETRICS, 207,646 IMASIS) were included in the general population cohort. RA and SLE cohorts enrolled 135,259 and 39,295 patients, respectively, in PHARMETRICS. Incidence of MTX and HCQ were stable before March 2020. On March 2020, the incidence of HCQ increased by 9‐ and 67‐fold in PHARMETRICS and IMASIS, respectively, and decreased in May 2020. Usage rates of HCQ went back to prepandemic trends in Spain but remained high in the United States, mimicking waves of COVID‐19. No significant changes in HCQ use were noted among patients with RA and SLE. MTX use rates decreased during HCQ approval period for COVID‐19 treatment.

Conclusion

Use of HCQ increased dramatically in the general population in both Spain and the United States during March and April 2020. Whereas Spain returned to prepandemic rates after the first wave, use of HCQ remained high and followed waves of COVID‐19 in the United States. However, we found no evidence of general shortages in the use of HCQ for both RA and SLE in the United States.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxychloroquineLupus Erythematosus, SystemicArthritis, RheumatoidAntirheumatic AgentsCOVID-19HumansFemaleMaleMiddle AgedAdultSpainUnited StatesCOVID-19 Drug TreatmentAgedIncidenceSARS-CoV-2

Substanzen

HydroxychloroquineAntirheumatic Agents

Autor:innen und Institutionen

  • Pharmaco- and Device Epidemiology Group, Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, United Kingdom and Fundació In…
  • Pharmaco- and Device Epidemiology Group, Health Data Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, United Kingdom.
  • Hospital del Mar Research Institute and Pompeu Fabra, Barcelona, Spain.
  • Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla IBiS, and Universidad de Sevilla CSIC, Andalusia, Spain.
  • Universidade Europeia, Lisbon, Portugal.
  • Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.

ORCID-Profile: Núria Mercadé-Besora, Edward Burn, Daniel Prieto-Alhambra

Förderung

  • Innovative Medicines Initiative (IMI)
  • NIHR Senior Research Fellowship, NIHR
  • International Magnesium Institute

Zitieren

APA

Mercadé-Besora, N., Guo, Y., Du, M., Li, X., Ramírez-Anguita, J. M., Moreno, A., Valente, A., Villalobos, F., Cheng, I. L., Carrasco-Ribelles, L. A., van Swieten, M. M. H., Merkelbach, M., Magoya, M., Lasalvia, P., Pericàs-Pulido, P., Berg, P., Bosco-Lévy, P., Lillini, R., Ribeiro, R., …, & Prats-Uribe, A. (2024). Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic. Arthritis Care & Research. https://doi.org/10.1002/acr.25331

Vancouver

Mercadé-Besora N, Guo Y, Du M, Li X, Ramírez-Anguita JM, Moreno A, et al. Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic. Arthritis Care & Research. 2024. doi:10.1002/acr.25331

BibTeX
@article{MercadBesora2024,
  author = {Mercadé-Besora, Núria and Guo, Yuchen and Du, Mike and Li, Xintong and Ramírez-Anguita, Juan Manuel and Moreno, Alberto and Valente, António and Villalobos, Felipe and Cheng, Iek Leng and Carrasco-Ribelles, Lucía A and van Swieten, Maaike M H and Merkelbach, Manon and Magoya, Mary and Lasalvia, Paolo and Pericàs-Pulido, Pau and Berg, Paul and Bosco-Lévy, Pauline and Lillini, Roberto and Ribeiro, Rogerio and Bagga, Trinamjot Kaur and Ramella, Vittoria and Khalid, Sara and Mayer, Miguel Angel and Leis, Angela and Jödicke, Annika M and Burn, Edward and Prieto-Alhambra, Daniel and Català, Martí and Prats-Uribe, Albert},
  title = {Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic},
  journal = {Arthritis Care & Research},
  year = {2024},
  doi = {10.1002/acr.25331}
}
Kostenlos starten →